Anthony G. Quinn, President & CEO at Aeglea BioTherapeutics, Inc. (AGLE), bought 49,375 shares at $6.56 ($334K) on 2019-05-20, disclosed to the SEC on 2019-05-22.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.56 | 8,989 | $59K | 17.6% |
| 2 | $6.56 | 8,989 | $59K | 17.6% |
| 3 | $6.89 | 13,794 | $95K | 28.4% |
| 4 | $6.89 | 13,794 | $95K | 28.4% |
| 5 | $6.86 | 3,809 | $26K | 7.8% |
| Total | $6.77 avg | 49,375 |
| $334K |
| 100% |
| Filing → |
| AGLE | BUY | 2022-03-18 | $375K | — | Filing → |
| AGLE | BUY | 2022-03-15 | $562K | — | Filing → |
| AGLE | BUY | 2021-12-13 | $358K | — | Filing → |